A Phase 4 interventional study of Combined therapy of Iguratimod and tofacitinib in Rheumatoid Arthritis (RA, sponsored by Jie Chang. Not yet recruiting at 1 site in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-04-25.
Sponsored by Jie Chang · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 249 studies in Arthritis, Rheumatoid with a site in China — 63 open to participants now, 72 under way, 3 of them phase 3. Arthritis, Rheumatoid · China.
Among the 249 studies in Arthritis, Rheumatoid with a site in China, this one is the 75th largest by planned enrollment of the 217 interventional ones that give a count, is one of 35 that started in 2025, is one of 28 in phase 4, reaches primary completion later than 36 of the 71 other live ones, and was the 200th registered.
3,339 studies on the registry are indexed under Arthritis, Rheumatoid; 446 are open to participants now.
Browse Arthritis, Rheumatoid studies →63 of the 249 studies in Arthritis, Rheumatoid with a site in China are open now. Recruiting first, the newest first:
Bristol-Myers Squibb · Sites in China, United States, Belgium and 8 more countries
Ages 18–65
Peking University People's Hospital · Sites in China
Ages 18+
Jacobio Pharmaceuticals Co., Ltd. · Sites in China
Ages 18–75
Peking Union Medical College Hospital · Sites in China
Ages 18–65
The First Affiliated Hospital with Nanjing Medical University · Sites in China
Ages 18–70
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 293 Arthritis, Rheumatoid studies recruiting now, 151 (52%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
249 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 58 · Phase 2 46 · Phase 3 52 · Phase 4 28
First in 2003; this study’s year is marked. 35 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 200 is above the median of 96 across 2,226 interventional studies indexed under Arthritis, Rheumatoid.
Median enrollment 134 across the 217 interventional studies, 287 across the 32 observational. Of the 115 that completed or were terminated, 28 (24%) have results posted.
This tab as a report to print or save as PDF → With an account.
129 of 249 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with Jie Chang as lead sponsor.
Jie Chang has 1 study filed under Arthritis, Rheumatoid — fewer than ten, so there is no comparison to draw.
16 of the studies in Arthritis, Rheumatoid with a site in China that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06887127Phase 3Hangzhou Highlightll Pharmaceutical Co., LtdA Long-term Extension Clinical Study of TLL-018 in Patients With Rheumatoid Arthritis | 2026-12-31 |
| NCT07408024Toll Biotech Co. Ltd. (Beijing)Safety and Efficacy of TollB-001 Tablets in Moderate to Severe Rheumatoid Arthritis | 2026-12 |
| NCT07045896Peking University People's HospitalFucoidan in the Treatment of Active Rheumatoid Arthritis | 2026-12 |
| NCT06945666Jie ChangA Study of Iguratimod in Combination With Tofacitinib in RA Patients | 2027-01-31 |
| NCT07491016Zhejiang Provincial People's HospitalEfficacy and Safety of Telitacicept Combined With Baricitinib for Refractory Rheumatoid Arthritis | 2027-03-30 |
Add all 16 to your calendar (.ics) → With an account.
Among the 249 studies in Arthritis, Rheumatoid with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Rheumatoid arthritis (RA) is a common chronic inflammatory autoimmune disease characterized by synovitis, which can cause joint pain, deformity, and extra-articular symptoms, seriously affecting the quality of life and lifespan of patients. Currently, the treatment of RA adopts a target attainment strategy, aiming to control the disease and reduce the disability rate. Although traditional disease-modifying antirheumatic drugs (DMARDs) can alleviate symptoms, they have slow onset, many side effects, and cannot completely stop the disease progression. Among biological DMARDs (bDMARDs), tumor necrosis factor-α (TNF-α) inhibitors have better effects, but some patients have poor responses and their conditions are not effectively controlled, thus new treatment options are urgently needed. This study aims to evaluate the efficacy and safety of the combination of iguratimod and tofacitinib in the treatment of RA patients with poor responses to traditional or biological DMARDs, providing evidence-based support for clinical treatment.
This protocol is a multicenter, prospective study on the treatment of RA patients with poor response to conventional or biological DMARDs using a combination of iguratimod and tofacitinib. The study will be conducted simultaneously at 8 research centers, and each center will strictly follow the unified research protocol and standard operating procedures.
Researchers are not allowed to interfere with the treatment of patients. The treatment and follow-up arrangements are determined by the prescribing doctor based on the actual clinical situation. Enrolled patients receive standard-dose treatment with aramodine combined with tofacitinib. The recommended dose of iguratimod is 25mg twice a day, and the recommended dose of tofacitinib is 5mg twice a day. During the treatment period, other background treatment drugs (decided by the prescribing doctor) are allowed, but other anti-rheumatic drugs that may affect the research results are not allowed, in order to simulate the real clinical diagnosis and treatment environment to the greatest extent and ensure the extrapolation of the research results.
The observation period was from the time of patient enrollment to 24 weeks after the end of treatment. For patients who experienced serious adverse events (SAEs), follow-up was conducted until the outcome was clear or the study was terminated. During the study, the patients' disease conditions, adverse drug reactions, and other situations were closely monitored. At each follow-up visit, the researchers would record the patients' symptoms and signs in detail, conduct relevant laboratory tests and necessary imaging examinations, and comprehensively assess the patients' disease status and treatment effects.
This study adopts a parallel controlled design, setting up a combined treatment group without an additional control group. The focus is on evaluating the efficacy and safety of the combined treatment plan in the target patient population. Through multi-center collaboration, data from patients with different characteristics in various regions will be extensively collected to enhance the representativeness and reliability of the research results. Meanwhile, to ensure the quality of the research data, a complete data management and quality control system will be established. Regular audits and evaluations of the data from each center will be conducted to promptly identify and correct any issues in the data.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
This study adopted a parallel controlled design, setting up a combined treatment group without an additional control group. The patients in the group received treatment with the standard dose of Iguratimod combined with tofacitinib. The recommended dose of Iguratimod is 25mg bid and that of tofacitinib is 5mg bid. During the treatment, other background therapeutic drugs were allowed to be used (determined by the prescribers), but other anti-rheumatic drugs that affected the study results were not allowed.
Drug: Combined therapy of Iguratimod and tofacitinib
This study aims to evaluate the efficacy and safety of the combination of iguratimod and tofacitinib in the treatment of RA patients with poor responses to traditional or biological DMARDs, providing evidence-based support for clinical treatment.
Also known as: Combined therapy, Iguratimod and tofacitinib
ACR20 (%)
American College of Rheumatology 20% improvement criteria (ACR20) response rates(Expressed as a percentage value) at 12 and 24 weeks of treatment.
Time frame: 12 and 24 weeks of treatment
ACR50 (%)
American College of Rheumatology 50% improvement criteria (ACR50) response rates(Expressed as a percentage value) at 12 and 24 weeks of treatment.
Time frame: 12 and 24 weeks of treatment
ACR70 (%)
American College of Rheumatology 70% improvement criteria (ACR70) response rates(Expressed as a percentage value) at 12 and 24 weeks of treatment.
Time frame: 12 and 24 weeks of treatment
DAS28
Changes in disease activity score (DAS28) from baseline at 12 and 24 weeks of treatment. This score has no unit of measure.
Time frame: 12 and 24 weeks of treatment
ESR (mm/h)
Changes in erythrocyte sedimentation rate (ESR, millimeters per hour) from baseline at 4, 8, 12, and 24 weeks of treatment.
Time frame: 4, 8, 12, and 24 weeks of treatment
CRP (mg/L)
Changes in C-reactive protein (CRP, milligrams per liter) levels from baseline at 4, 8, 12, and 24 weeks of treatment.
Time frame: 4, 8, 12, and 24 weeks of treatment
RF (IU/L)
Changes in rheumatoid factor (RF, international units per liter) levels from baseline at 4, 8, 12, and 24 weeks of treatment.
Time frame: 4, 8, 12, and 24 weeks of treatment
CCP (U/L)
Changes in anti-cyclic citrullinated peptide antibody (CCP, units per liter) levels from baseline at 4, 8, 12, and 24 weeks of treatment.
Time frame: 4, 8, 12, and 24 weeks of treatment
AE
Incidence of adverse events (AE) of different severity
Time frame: From baseline to 24 weeks of treatment
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Aug 2025; primary completion for Jan 2027, 17 months later.
Of 79 non-industry phase 4 interventional studies under Arthritis, Rheumatoid, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 92. This study's planned 17 months is below that.
Counting every sponsor, half of 104 studies reached it within 42 months; a quarter within 25 and three quarters within 74.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.